(Q44795652)

English

Immunophenotypic normalization of aberrant mast cells accompanies histological remission in imatinib-treated patients with eosinophilia-associated mastocytosis

scientific article published in May 2004

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Immunophenotypic normalization of aberrant mast cells accompanies histological remission in imatinib-treated patients with eosinophilia-associated mastocytosis (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

0 references

4

object named as

Tefferi A

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

author name string

Elliott MA

1

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Pardanani A

2

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Li CY

3

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

publication date

1 May 2004

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

1027-1029

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403329

21 January 2018

Treatment of hypereosinophilic syndrome with imatinib mesilate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403329

21 January 2018

Imatinib for systemic mast-cell disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403329

21 January 2018

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403329

21 January 2018

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403329

21 January 2018

Differential expression of CD2 on neoplastic mast cells in patients with systemic mast cell disease with and without an associated clonal haematological disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403329

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2403329

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44795652&oldid=2206927092"